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A particularly challenging subpopulation of prostate cancer patients are those who present with a 
persistently elevated PSA and suspicion of prostate cancer despite having had one or more prior negative 
prostate biopsies. These patients may benefit from the improvements made in prostate imaging through 
multiparametric MRI (mpMRI) and MRI-guided prostate biopsy techniques. In this study, we evaluate mpMRI 
and MRI-US fusion biopsy as a means of detecting clinically significant cancer as well as a potential 
indicator for avoiding repeat biopsies. We performed a retrospective study of 374 men seen between 
12/2012 and 06/2015. All patients underwent pre-biopsy mpMRI to identify regions of interest (ROIs) within 
the prostate and each was assigned an MRI suspicion score. All patients then underwent a 12-core standard 
trans-rectal mapping biopsy, and all patients with ROIs identified on mpMRI underwent MRI-US fusion 
targeted biopsy. We defined cancer as any Gleason score ≥ 6, and we defined clinically significant cancer 
as Gleason score ≥ 3+4. Statistical analysis was performed using chi squared, Fisher’s exact, student’s t-
test, one-way ANOVA, and multivariate logistic regression. All test results were considered statistically 
significant if p < 0.05. 143 patients were included in our analysis. Overall cancer detection rate was 42.66%, 
and the clinically significant cancer detection rate was 27.27%. For standard 12-core mapping biopsy, the 
cancer detection rate was 34.97%, and the clinically significant cancer detection rate was 18.18%. For men 
who underwent targeted biopsies, the cancer detection rate of the targeted biopsies was 40.5%, and the 
clinically significant cancer detection rate was 27.27%. In total, 21.50% of patients were upgraded by 
inclusion of targeted biopsy. For the 72 patients with no cancer on targeted biopsy, only 2 were found to 
have clinically significant cancer on mapping biopsy. A total of 213 ROIs were identified following mpMRI. 
Cancer was found in 32.86% of the ROIs and clinically significant cancer was found in 22.54%. For the 22 
patients with no target identified on MRI, none were found to have clinically significant cancer. Age, PSA, 
MRI suspicion score, and PSA density were correlated with clinically significant. Anterior location of ROI was 
significantly correlated with presence of cancer and higher grade cancer, particularly on targeted biopsy. For 
clinically significant cancer detected on targeted biopsy, multivariate logistic regression revealed that the 
only significant independent predictor of disease was the presence of an anteriorly located ROI on mpMRI 
(OR 4.50, p < 0.01). In men with one or more previous negative biopsies and continued suspicion for 
prostate cancer, mpMRI and MRI-US fusion targeted biopsy provide greater detection rate of clinically 
significant disease compared to standard 12-core TRUS biopsy. Men with negative MRI findings may be 
able to avoid or delay biopsy. Patients with high MRI suspicion score lesions and those with anterior lesions 
are at increased risk for significant disease and should be treated with the necessary diligence.  
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Prostate cancer is the most commonly diagnosed cancer in males in the United 
States, with an estimated 181,000 new cases and 26,000 deaths in 2016. 
Currently, the estimated lifetime risk of developing prostate cancer is 
approximately one in seven 1. Annual rates of prostate cancer detection have 
varied over the years. With the advent of PSA testing in the late 1980s, the 
prostate cancer incidence rose dramatically, peaking in the early 1990s 2. Rates 
of detection have since declined as the focus has shifted away from widespread 
PSA screening in order to minimize over-detection of clinically insignificant 
tumors 3. Meanwhile, rates of death from prostate cancer have declined steadily. 
Currently, lifetime risk of death from prostate cancer is less than 3%, and the 5-
year survival rate for a new diagnosis of prostate cancer is greater than 99%. 
Furthermore, the majority of prostate cancer deaths occur after the age of 75 1,3. 
Though prostate cancer incidence has fluctuated over the past few 
decades as screening guidelines and practices have changed, the true 
prevalence of the disease remains difficult to measure. Prostate cancer is rarely 
diagnosed as a result of clinical symptoms, with physicians relying on screening 
exams and subsequent biopsies to drive the detection of the disease. This is 
illustrated well in studies that compared histological examination of autopsy 
specimens from men who died with no clinical evidence of prostate disease, 
where the prevalence of malignancy is much higher than the corresponding age-
adjusted incidence 4. A recent systematic review of autopsy studies spanning the 
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1940s to the 2010s demonstrated varying prevalence of prostate cancer. Across 
different age groups, cancer prevalence on autopsy ranged from 0% for patients 
younger than 30 years old to more than 70% for patients greater than 70 years 
old 5.  
 
Risk Factors 
Several risk factors have been identified that are associated with being 
diagnosed with prostate cancer. The three primary risk factors associated with 
the disease are age, race or ethnicity, and family history of the disease 6. Age 
has the strongest association with the development of prostate cancer and has 
been identified as a possible predictive factor, with an odds ratio of 1.71 per 
decade identified by investigators in the systematic review of autopsy studies 5. 
Race has been identified as a significant prostate cancer risk factor, with Black or 
African-American men at a 1.6 times higher risk of diagnosis and a 2.5 times 
higher risk of death than Caucasian men. African-American and Jamaican men 
have been shown to have the highest rates of prostate cancer, while Asian men 
have a lower rate than that of Caucasians. Interestingly, minority groups such as 
Asians, Hispanics, and Native Americans have lower rates of disease than White 
Americans, but are thought to be at higher risk as they are more assimilated into 
American society. Investigations into possible environmental drivers of racial 
disparity such as diet and obesity rates have not yielded convincing results, 
though literacy and education have been correlated with increased stage at 
presentation and greater risk of prostate cancer death, respectively 6. 
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Finally, prostate cancer has been known to demonstrate clustering within 
families, with 10-15% of patients having at least one other family member 
afflicted by the disease. Studies have demonstrated at least a two-fold increase 
in risk in patients with one affected first degree relative such as a father or 
brother 7. A Swedish study from 2010 analyzed over 3.9 million men and 
included over 25,000 cases of prostate cancer. Hazard ratios were reported for 
men with increasing number of family members affected by the disease. The 
hazard ratios were lowest at 1.8 for men with a father diagnosed later in his life 
and highest at 23 for men with three affected brothers diagnosed at a younger 
age. Generally, hazard ratios increased with decreasing age at diagnosis of the 
affected family members 8. Another large Scandinavian study examined cohorts 
of twin pairs, concluding that prostate cancer demonstrated higher concordance 
for cancer in identical twins than breast or colorectal cancer and suggesting that 
up to 42% of prostate cancer risk can be attributed to heritable factors 9. 
Genomic studies have revealed the complex nature of prostate cancer genetics, 
with many SNPs identified as independently associated with the disease 10. 
Other studies have emphasized the importance of BRCA1 and BRCA2 mutations 
on prostate cancer diagnosis and mortality, as well as increased risk related to 
HOXB13 germline mutations 11,12. 
 
Screening for Prostate Cancer 
While prostate cancer survival rates are excellent overall, there is a significant 
discrepancy between five-year survival rates for patients diagnosed with locally 
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or regionally contained disease and disease with distant metastases at the time 
of diagnosis. With the presence of distant metastases at the time of diagnosis, 
the five-year survival rate falls from 100% to a mere 28.2% 13. It is clear that 
prostate cancer is a disease with a broad range of lethality, considering the 
disparity in mortality between locally contained and disseminated disease, as 
well as the prevalence of incidental disease found on autopsy. In response, 
physicians have attempted to optimize population screening guidelines in order 
to prevent life-threatening cases while avoiding overdiagnosis of nonlethal 
disease. 
The oldest screening test for prostate cancer is the digital rectal 
examination, or DRE. It has been performed to detect nodules, asymmetry, or 
induration that may suggest the presence of tumors in the posterior and lateral 
aspects of the gland. Unfortunately, not all tumors arise in these locations 14. 
Furthermore, the effectiveness of the DRE as an exam has been called into 
question given the subjective nature of the test and the fair, but not great level of 
interrater agreement 15. A metaanalysis of DRE performance suggested a 
sensitivity of 59%, specificity of 94%, and a positive predictive value of only 28% 
16. 
Screening for prostate cancer with PSA testing began in the late 1980s, 
and in 1992 the American Cancer Society recommended annual screening with 
DRE and PSA for men over the age of 50 17. PSA is a glycoprotein produced 
specifically by prostate epithelial cells and has a half life of 2.2 days. Early 
analysis of PSA found a correlation between PSA levels and increasing clinical 
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stage, as well as cancer volume. Investigators noted, however the wide range of 
PSA levels in patients with locally confined disease and the elevation of PSA 
associated with benign prostatic hypertrophy. PSA was identified as an excellent 
tool for surveillance and detection of recurrent disease following surgical 
intervention or radiation therapy 18. Other studies have concluded that PSA 
elevations can precede detection of prostate cancer by five to ten years 19. 
However, reliability of PSA screening has been a topic of significant debate. PSA 
can be affected by a range of benign conditions, including ejaculation, acute 
urinary retention, inflammation or prostatitis, digital rectal exam, transrectal 
ultransonography, or prostate biopsy 20–22. Medications, especially five-alpha 
reductase inhibitors such as finasteride and dutasteride, may reduce PSA levels 
by as much as 50% 23,24. 
Evaluating the effectiveness of PSA has been challenging for a number of 
reasons. First, most men with normal PSA values do not undergo confirmatory 
biopsy, leading to a verification bias that overestimates sensitivity and 
underestimates specificity 25. Furthermore, PSA is usually compared to results of 
prostate biopsy, which in itself is an imperfect and evolving test 26. Nevertheless, 
the American Cancer Society performed a systematic review in 2009 to evaluate 
PSA screening. The investigators estimated that PSA screening with a cutoff of 
4.0 ng/mL led to a sensitivity of 21 percent for detecting any cancer and 51 
percent for detecting high grade disease, as well as a specificity of 91% 27. The 
positive predictive value of PSA screening has been best studied, with a 
multicenter clinical trial of over 6,000 men finding a positive predictive value of 
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32% for PSA over 4.0 ng/mL, but only 25% for men with PSA between 4.0 and 
10.0 ng/mL 28. Another large trial, the Prostate Cancer Prevention Trial, 
estimated negative predictive value of PSA under 4.0 ng/mL to be 85% after 
studying biopsies of men with normal PSA values 29. 
Multiple strategies have been proposed to attempt to increase the 
accuracy of PSA testing to improve detection of high risk disease. These include 
age- and race-specific cutoff values, measuring PSA values over time (PSA 
velocity) or with respect to prostate size (PSA density), and relative levels of free 
versus complexed PSA 30. Unfortunately, none of these methods has significantly 
improved the diagnostic accuracy of PSA 31–33. In 2012, after performing a review 
of the evidence regarding the efficacy of PSA screening, the USPSTF published 
new prostate cancer screening guidelines, giving PSA screening a D rating and 
recommending against its use 34,35. This recommendation was met with 
controversy, as some groups felt as though the USPSTF underestimated the 
benefits of screening while overstating the harms 36. The American Urological 
Association subsequently published a new recommendation encouraging 
providers to engage in shared decision making with patients and to explain the 
risks and benefits of PSA screening, especially to those at higher risk, such as 
African American men, and men with a life expectancy greater than 10 years 37.  
 
Diagnosis of Prostate Cancer 
Despite the controversy over screening and early detection of prostate cancer, 
many men continue to be referred to a urologist for evaluation following an 
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elevated PSA or abnormal DRE. Diagnosis of prostate cancer is performed 
through clinical examination combined with histological assessment of tissue 
obtained via prostate biopsy. Prostate biopsy is primarily performed via one of 
two anatomical approaches. The first and most common approach is the 
transrectal ultrasonography (TRUS)-guided prostate biopsy, a technique that was 
developed in the late 1980 and was formalized with the introduction of the TRUS-
guided systematic sextant biopsy protocol by Hodge in 1989 14. This procedure is 
commonly done in the office setting with local anesthesia, and involves a 
transrectal ultrasound probe through which spring-loaded needles may be 
inserted and guided into the different regions of the prostate 38. These regions 
include the anterior fibromuscular stroma, transition zone (TZ), central zone (CZ), 
periurethral zone, and peripheral zone (PZ). TRUS-guided biopsy assists the 
operator in obtaining samples from various regions of the prostate and at times 
the seminal vesicles, which are located posteriorly at the base of the gland. 
The number and distribution of sample cores taken has evolved over time. 
The original scheme included six cores – one from the base, mid, and apex of 
the gland on each side. This sextant protocol improved upon the previous 
standard, where samples were digitally directed 39. Subsequent pathological 
studies of radical prostatectomy specimens demonstrated that the majority of 
disease arises in the posterolateral PZ, and modifications to the sextant scheme 
were introduced to focus on sampling the lateral areas of the gland 40. The 
current method endorsed by the American Urological Association is the extended 
12-core systematic biopsy that includes apical and far-lateral cores 41. A 
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saturation biopsy with an increase in the number of cores to 18 or more on initial 
biopsy has not demonstrated the same benefit as the increase from six to 12, 
though studies have shown an decrease in clinically significant cancer detected 
on repeat biopsy after initial saturation biopsy 42. 
The transperineal prostate biopsy has typically been used as an 
alternative approach for patients who are unable to undergo a transrectal 
procedure. A 2008 prospective randomized trial compared the transperineal and 
transrectal approache and found no significant difference in cancer detection 
rates and complications between the two approaches 43. The authors concluded 
that the transrectal approach is preferred as it can be performed with local 
anesthesia, as opposed to the transperineal approach, which requires spinal or 
more generalized anesthesia. Recent reviews of the evidence, however, have 
argued for a larger role for transperineal biopsy, citing improved sampling of the 
anterior and apical sides of the prostate with lower false negative rate and 
reduced risk of underestimating disease grade 44. The authors argue that 
transperineal biopsy, though more costly than transrectal biopsy, may be 
especially useful for patients with a previous negative transrectal biopsy. 
With both types of biopsy method, there are risks and complications of the 
procedure. Prostate biopsy is generally well tolerated and considered a safe 
procedure, with less than 1% of patients suffering serious complications requiring 
hospitalization. The most common post-biopsy complications include infection, 
ranging from UTI and low-grade fever to sepsis, and bleeding. These risks are 
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mitigated through prophylactic antibiotic administration and periprocedural 
management of the minor complications that may arise 14. 
 
Prostate Cancer Clinical Staging 
The clinical staging of prostate cancer takes into account multiple pretreatment 
parameters to predict the extent of the disease. This allows for an assessment of 
prognosis and helps providers and patients to select the best option for initial 
management. The parameters that are considered for clinical staging are DRE, 
PSA and related blood tests, tissue histology on needle biopsy, and results of 
imaging 14. The current system of clinical staging is based on the tumor, node, 
metastasis (TNM) classification system first adopted by the American Joint 
Committee on Cancer (AJCC) in 1975 and modified for prostate cancer in 1992 
45. The latest version from the AJCC combines TNM stage with PSA value and 
histological grade to categorize patients into one of four prognostic groups 46. 
Histologic grading of tissue obtained through prostate biopsy is performed 
using the Gleason grading system 47. The system involves taking the sum of the 
predominant grade at low-power magnification and the grade of the second most 
common pattern in the sample to yield a score from 2 to 10. More recent 
research and discussion regarding Gleason scores has focused on the effect that 
tertiary Gleason patterns may have, especially when they are grade 5. 
Furthermore, Gleason 6 scores have been identified to be of low risk, and 
stratification between Gleason 3+4 and 4+3 tumors has been suggested 14. 
Higher Gleason score is associated with worse prognosis, but other factors such 
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as PSA level, number of positive cores, percentage of positive cores, and 
presence of perineural invasion are taken into account when performing risk-
stratification 48. Risk nomograms that predict pre-operative extent of disease 
have been developed from institutional experience, and other validated 
classification schemes such as the Cancer of the Prostate Risk Assesment 
(CAPRA) score have been developed to help predict longer term outcomes 
following treatment 49,50.   
 
Initial Management of Prostate Cancer 
Following prostate cancer tissue diagnosis from biopsy, initial staging should be 
completed for patients with Gleason 7 or greater with a radionuclide bone scan 
and abdominal-pelvic CT or MRI scan in order to best direct initial management. 
Depending on the prognostic risk group that the patient falls into, there are many 
different options available for initial disease management. The most conservative 
of these are watchful waiting and active surveillance. Watchful waiting typically 
refers to the observation of a patient who will develop metastases and then 
require palliative care, while active surveillance, also known as expectant 
management, allows for the delay of primary treatment until there is biochemical 
or histological evidence of cancer progression. Active surveillance is typically 
reserved for patients with low-risk disease (Gleason score < 6, PSA < 10 and 
clinical stage < T2a), though it may have some benefit for patients with Gleason 
7 (3 + 4) tumors 51. It has typically been used for men with a life expectancy < 10 
years, although rates of active surveillance are increasing and include younger 
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men 52. Because delaying treatment may lead to cancer progression and loss of 
curative potential, these initial management decisions must be carefully 
considered 53. Investigators have constructed statistical models to predict which 
tumors are likely to progress and which are likely to remain indolent. The Epstein 
criteria, established in 1994, identified factors such as tumor volume < 0.2 cm3 
and Gleason score < 7 that predict the presence of “clinically insignificant” 
disease, as evaluated on pathological staging 54. These criteria were updated in 
1998 to include a free/total PSA ratio (0.15 or greater) and other favorable needle 
biopsy findings (fewer than three cores involved and < 50% of any one core) to 
attain a positive predictive value of 95% and a negative predictive value of 77.2% 
for “insignificant” tumors 55. 
While active surveillance may be the optimal choice for patients with low 
risk disease, patients with clinically significant tumors require interventional 
treatment. The primary categories of established treatments include radiation 
therapy and radical prostatectomy. Hormone therapy with androgen deprivation 
is most often used in conjunction with radiation therapy as a primary treatment 
option. Androgen deprivation therapy (ADT) is generally recommended for 
unfavorable intermediate-risk, localized high-risk, and locally advanced prostate 
cancer based on results of clinical trials involving patients with locally advanced 
prostate cancer 56. ADT has also been employed in the salvage setting, and was 
previously used for primary therapy as a palliative care for men with shorter life 
expectancy who did not wish to seek more aggressive treatment 14. However, a 
recent trial comparing 15,000 men who received ADT with no other treatment 
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showed no mortality benefit 57. Meanwhile, the risks of associated with ADT have 
been well described and include increased risk of diabetes and cardiovascular 
disease 58. ADT is still being evaluated in clinical trials as an adjunct to salvage 
radiotherapy. 
Radiation therapy and radical prostatectomy are typically considered the 
two primary options to provide biochemical control over prostate cancer. There 
are two main categories of radiotherapy, external beam radiation therapy, and 
brachytherapy. External beam radiation therapy includes intensity-modulated 
radiation therapy (IMRT), stereotactic body radiation therapy, and heavy-particle 
radiotherapy. IMRT is a sophisticated form of 3D conformal radiotherapy that 
utilizes computers to focus the photon radiation dose to the prostate in an effort 
to deliver maximum effect while minimizing radiation of adjacent structures 59. 
Stereotactic body radiation therapy, also known as Cyberknife, delivers higher 
doses of radiation over much smaller periods of time, a process known as 
hyperfractionation. The cost is less than that of IMRT and initial results show 
similar treatment efficacy, though longer term results are not yet available 60. 
Heavy-particle radiotherapy utilizes proton or neutron beams and has the 
potential for even more focused radiation delivery, though at increased cost 14. 
Early results suggest that heavy-particle radiotherapy is comparable to IMRT in 
clinical and quality of life measures 61,62. Brachytherapy involves the implantation 
of radioactive seeds or needles into the prostate gland to deliver a high dose of 
radiation and has been shown to be effective in patients with low- and 
intermediate-risk localized disease 63. While radiotherapy can deliver targeted 
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treatment, side effects including gastrointestinal and urinary morbidity and 
erectile dysfunction 61. 
Radical prostatectomy was the first treatment developed for prostate 
cancer, with earliest reports dating back to Kuchler in 1866 and Young in 1905 at 
Johns Hopkins 14. Despite its complexity and considerable risks of side effects, 
the procedure remains the gold standard in attempting a curative intervention. 
Radical prostatectomy may be performed through one of a few different 
approaches, including perineal, open retropubic, laparoscopic, and robotic. There 
has been debate regarding the optimal approach, especially in context of the rise 
in popularity of robotic prostatectomy since its introduction in 2000 with the da 
Vinci Surgical System. Studies comparing the robotic approach to the open 
retropubic approach have concluded that the two methods are comparable on 
functional and oncologic outcomes, while other studies have demonstrated more 
favorable rates of side effects for each 64–66. The primary advantage of the radical 
prostatectomy over other forms of treatment is its potential for cure with minimal 
collateral damage when correctly and skillfully performed 67. Additionally, more 
accurate tumor staging may be performed upon pathological examination of the 
surgical specimen, and treatment failure is more easily identified, allowing for 
timely initiation of salvage therapy 14. Disadvantages of radical prostatectomy 
include the necessary hospitalization and postoperative recovery, possibility of 
incomplete resection, and risk of erectile dysfunction and urinary incontinence. 
The “trifecta” of priorities for radical prostatectomy include cancer control, 
preservation of continence, and preservation of potency 68. Generally, younger, 
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healthier men with life expectancy of at least ten years are the best candidates 
for radical prostatectomy. 
 
Importance of Representative Tissue Sampling 
The choice of optimal therapy depends greatly upon the patient’s risk group and 
life expectancy 14. In turn, the risk group is heavily influenced by clinical stage. A 
continued concern with current prostate biopsy methods is the risk for non-
representative tissue sampling. Patients who are categorized as low-risk 
following prostate biopsy that demonstrated Gleason 6 disease may enter an 
active surveillance protocol only to find that higher grade disease was present in 
their prostate but did not happen to be detected by one of the 12 cores. In a 2012 
systematic review, investigators found that 42% of men who would have fallen 
into the D’Amico low-risk group were found to have an increase in Gleason score 
following rebiopsy or pathological analysis of radical prostatectomy specimen. 
When using Epstein criteria, an increase in risk group was found in 34% of 
patients 69. A 2010 study found that 47% of active surveillance patients 
undergoing radical prostatectomy were found to have Gleason 7 or greater 
disease 70. In a recent Swedish study of men with very low risk prostate cancer 
(T1c, PSA concentration less than 10 ng/ml, PSA density < 0.15 ng/ml2, Gleason 
6 in up to 4 positive biopsy cores with a total biopsy cancer length of ≤ 8 mm) 
who underwent radical prostatectomy, 34% had upgrading to stage pT3 or 
Gleason 7 or higher 71. Another study that used modified Epstein criteria (PSA < 
10 ng/ml, positive biopsy cores ≤ 3, and maximum involvement of any single core 
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≤ 50%) found that in men who were considering active surveillance and had a 
rebiopsy within three months of initial biopsy, 27% were upgraded or upstaged 
on repeat biopsy. These men were also significantly less likely to have organ 
confined disease or Gleason 6 or lower disease upon prostatectomy 72. On the 
other side, we would prefer to detect fewer indolent tumors that are truly clinically 
insignificant in order to avoid overdiagnosis and the accompanying increases in 
costs and morbidity. 
 
Use of MRI in Prostate Cancer Diagnosis 
As discussed above, introduction of TRUS significantly increased the cancer 
detection rate of transrectal prostate biopsy 39. However, TRUS imaging has 
been unable to reliably identify and localize tumors within the prostate 73. In fact, 
TRUS was shown to be no better than DRE in predicting disease outcome 74. 
Another imaging modality, MRI, has also long been investigated for its ability to 
assist with clinical staging. For many years, however, MRI did not demonstrate 
consistency in localizing tumors within the gland 75. However, recent advances in 
MRI imaging have allowed for reevaluation of the utility of MRI in prostate cancer 
diagnosis. Multiparametric MRI (mpMRI) is a type of study that involves multiple 
MRI sequences including T2-weighted imaging, diffusion weighted imaging, and 
perfusion imaging and presents the individual sequences in an integrated 
manner 76. Studies have demonstrated that mpMRI is the most accurate 
noninvasive technique to localize prostate cancer and can assist in risk 
stratification 77. A study by Rosenkrantz et al evaluated the ability of mpMRI to 
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localize index lesions later identified on pathological specimen. Across six 
different MRI readers, the investigators found an average sensitivity of 60.2% 
with positive predictive value of 65.3% for an exact match, and an average 
sensitivity of 75.9% with positive predictive value of 82.6% for an approximate 
match 78. MpMRI has also been shown to have high negative predictive value for 
the presence of extracapsular extension in low risk patients and high positive 
predictive value for local disease advancement in high risk patients 79. With the 
success of mpMRI in identifying prostate lesions, scoring systems have been 
adopted, including a three or five point Likert scale based on impression and the 
PI-RADS classification system based on fixed criteria 80,81. These MRI suspicion 
scores have been demonstrated to be strongly correlated with higher grade 
disease, and are thought to be a clinically useful parameter to help characterize 
prostate cancer 82,83. 
 
MRI-Guided Biopsy Techniques 
With better localization of tumors in the gland through mpMRI, new biopsy 
techniques have been developed to attempt to target the suspicious region of 
interest (ROI) identified on imaging studies. These MRI-guided targeted TRUS 
biopsies include visual estimation or cognitive fusion biopsy, in-bore biopsy, and 
software co-registered fusion biopsy. Visual estimation, also known as MRI 
cognitive fusion, is the least costly MRI-guided biopsy technique but lacks real 
time feedback and carries significant interoperator variability and learning curve. 
Some studies have found a lower cancer detection rate with visual estimation 
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than systematic or template biopsy, while others have found significantly higher 
rates of cancer detection with MRI-guided visual estimation 76. In-bore MRI-
guided biopsy involves performing prostate biopsy while the patient remains 
inside the MRI unit. Due to the vast increase in cost compared to TRUS-guided 
biopsy, in-bore MRI-guided biopsy has generally been reserved for patients who 
have had a prior negative biopsy with continued suspicion for prostate 
malignancy. Many studies have demonstrated a cancer detection rate above 
40% with 80-90% of tumors being clinically significant 84. 
Software co-registered MRI-guided biopsy is typically achieved through 
co-registration of the MRI image with a series of TRUS images that are taken at 
the time of the biopsy. The software then constructs a three-dimensional 
rendering of the prostate gland and aligns the biopsy with the co-registered 
image of the ROIs seen on mpMRI. These MRI-US fusion biopsy devices are 
manufactured by various companies and involve a high up-front investment as 
well as a learning curve for its utilization 76. MRI-US fusion biopsy has 
demonstrated to be more likely to detect cancer than standard 12-core TRUS 
biopsy, detect more cancer per core, upgrade Gleason scores when compared to 
12-core biopsy, and detect more high-risk prostate cancer while detecting less 
low-risk prostate cancer 85–88. In a recent meta-analysis of studies evaluating 
MRI-guided biopsy techniques, investigators did not find a difference in overall 
cancer detection rate, but did observe a higher rate of detection of clinically 





Men with Prior Negative Biopsy 
A particularly challenging subpopulation of prostate cancer patients are those 
who present with a persistently elevated PSA and suspicion of prostate cancer 
despite having had one or more prior negative prostate biopsies. Following a 
negative prostate biopsy, the information provided by serial serum PSA and PSA 
kinetics is limited, and many patients ultimately undergo repeated biopsy 
procedures in search of a histological answer for persistently elevated serum 
PSA. These repeat biopsies may be unnecessary, and, furthermore, may lead to 
overdiagnosis of clinically insignificant prostate cancer and subsequent 
overtreatment. The risk of missing clinically significant disease, especially in the 
context of the imperfect sampling methods of standard TRUS-guided 12-core 
biopsy, has prompted some men to receive as many as 10 prostate biopsies 90. 
For patients with at least one negative prostate biopsy, previous studies 
have described cancer detection rates on subsequent biopsies. Overall, cancer 
detection rates on repeat biopsies are significantly lower than on an initial biopsy 
with the standard TRUS-guided 12-core approach 91. In a retrospective study of 
2,500 men who underwent up to 10 repeat biopsies, Roehl et al. found that the 
serial cancer detection rates were 29%, 17%, 14%, 11%, 9% and 7%, on the first 
six successive biopsies 90. Low diagnostic yield was also found when men with 
prior negative biopsies underwent saturation biopsy to attempt to detect 
significant disease 92. Contrarily, a recent study found a CDR of 25% on the 
fourth biopsy in a cohort of 255 men with initial negative biopsy 93.  
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With the improvements made in prostate imaging through mpMRI and the 
development of new MRI-guided prostate biopsy techniques, patients with prior 
negative biopsies may benefit from these advances. Many studies have 
demonstrated the utility of mpMRI and MRI-guided biopsy for these patients. 
Cancer detection rates superior to standard TRUS biopsy have been described, 
as well as a greater proportion of clinically significant disease among detected 
cancers 94,95. Another recent study found an increased cancer detection rate as 
well as improved risk stratification with repeat biopsies using mpMRI and MRI-US 
fusion biopsy 96. This value of mpMRI has also been well documented, and MRI 
suspicion scores have been shown to be a strong predictor of significant cancer 
detection on subsequent MRI-guided biopsy 97–99. Furthermore, a systematic 
review demonstrated that in men with at least one negative prior biopsy, the two-
thirds (328 of 479) with an MRI abnormality led to a positive biopsy rate of 70% 
(229 of 328) when rebiopsied using an MRI-guided procedure 100. This has led 
some investigators to suggest using mpMRI as a screening tool to help reduce 
the number of unnecessary biopsies in men with prior negative biopsy results 101. 
In this paper, we evaluate mpMRI and MRI-US fusion biopsy as a means of 






We performed a retrospective study utilizing data collected from clinical 
encounters between 12/2012 and 06/2015. During this period, 374 men with an 
indication for prostate biopsy presented to our institution. All patients underwent 
pre-biopsy mpMRI which was subsequently read by experienced radiologists 
who identified any region of interest (ROI) and assigned a MRI suspicion score 
based on either a 3-point Likert scale or the PI-RADS classification system. All 
patients then underwent a 12-core standard trans-rectal mapping biopsy, and all 
patients with ROIs identified on mpMRI underwent MRI-US fusion targeted 
biopsy of those lesions with at least one biopsy core taken per target. All targeted 
biopsies were performed using the Artemis/Pro-Fuse™ system (Eigen, Grass 
Valley, California). 
Other members of the prostate cancer research group led by Dr. Preston 
Sprenkle created a secure database of patient information stored on a secure 
Yale server. The data entered in the database was retrospectively encoded from 
information found in the patient electronic medical record, including procedure 
notes and pathology reports. This data was then downloaded and transferred in 
deidentified form. 
From among this set, only men with at least one previous biopsy and no 
diagnosis of prostate cancer were included in our analysis. Variables included in 
the data analysis consist of the following: patient age, serum PSA level at time of 
biopsy, number of previous biopsies, prostate volume measured on MRI, 
prostate volume measured on TRUS, MRI result, MRI suspicion scores for each 
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ROI, location for each ROI, clinical stage, and information for each biopsy core 
taken including location, primary Gleason pattern, secondary Gleason pattern, 
percent of core occupied by cancer, length of cancer in each core, and qualitative 
description of histology. Maximum Gleason score was then assigned on a per-
patient basis based on the highest Gleason score found on any mapping biopsy 
or targeted biopsy core. 
The author proceeded to process this data set and encode it to allow for 
data analysis. PSA density was calculated twice by dividing serum PSA level by 
prostate volume on TRUS and MRI. Location of ROI was encoded into four 
variables differentiating between left and right; anterior and postieror; base, mid-
gland, and apex; and McNeal zone of the gland. Because some patients had MRI 
suspicion score reported on a three point Likert scale while others were graded 
according to PI-RADS, we combined the MRI suspicion score into a single 
variable by translating PI-RADS scores to the three point Likert scale. Patients 
were then evaluated for the detection of cancer through each biopsy method. We 
defined cancer as any Gleason score ≥ 6, and we defined clinically significant 
cancer as Gleason score ≥ 3+4. 
Statistical analysis was performed by the author using Stata 13 software 
(Statacorp, College Station, Texas). Summary statistics included mean, standard 
deviation, median, minimum, and maximum. Comparative statistics between 
groups of patients were performed using chi squared, Fisher’s exact, student’s t-
test, and one-way ANOVA. Multivariate logistic regression was performed to 
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evaluate predictive qualities of patient characteristics. All test results were 





Upon analysis of the available data, 143 of the 374 patients met inclusion criteria. 
Analysis was performed at the patient level and the ROI level. 
 
Patient Characteristics 
The overall mean age of men included was 64.1 years with a minimum of 47 
years and a maximum of 82 years. Mean PSA at time of biopsy was 11.59 ng/mL 
with a minimum of 0.4 ng/mL and a maximum of 96.90 ng/mL. On average, men 
in this cohort had received 1.8 previous negative biopsies with the greatest 
number being 5. Mean MRI-measured prostate volume was 68.52 mL (16.5 – 
309) and mean TRUS-measured prostate volume was 67.67 mL (8.81 – 243). 
Mean PSA density was 0.20 ng/mL2 (0.01 – 1.82) when calculated with TRUS 
volume and 0.21 ng/mL2 (0.01 – 1.45) when calculated with MRI volume. Of the 
143 men, 139 (97.2%) successfully completed the pre-biopsy multiparametric 
MRI, while the remaining 4 were unable to tolerate a complete exam. 
 
MRI Results 
Twenty-two patients (15.38%) had no suspicious lesions seen on MRI. Two of 
the patients with an incomplete exam did not have suspicious lesions reported 
during the part of the exam that was completed. Of the patients with suspicious 
lesions identified on MRI, 24 patients (16.78%) had only low suspicion lesions, 
40 patients (27.97%) had at least one moderate suspicion lesion with no high 
suspicion lesions, and 55 patients (38.46%) had one or more high suspicion 
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lesion. Of patients with ROIs on mpMRI, 61 (50.41%) had at least one anteriorly 
located ROI. 
A total of 213 ROIs were identified following mpMRI. Of these 213, 
47.89% (102) were located on the left lobe of the gland and 51.64% (110) were 
located on the right lobe of the gland. There was no left vs right sided information 
for 1 ROI. Between anterior and posterior location within the gland, 33.33% (71) 
were located in the anterior portion while 64.79% (138) were located in the 
posterior portion of the gland. There was no anterior vs posterior information for 4 
of the ROIs. Among base, mid, and apex regions of the gland, 24.41% (52) were 
located in the base of the gland, 49.30% (105) were located mid-gland, and 
25.35% (54) were located in the apex of the gland. There was no information in 
this dimension for 2 of the ROIs. Regarding McNeal zone of the prostate gland, 
75.12% (160) were located in the peripheral zone, 18.78% (40) were located in 
the central or transitional zone, 3.29% (7) were located in the anterior stroma, 
and 0.47% (1) were located in the seminal vesicles. There was no McNeal zone 
information for 5 of the ROIs. The MRI suspicion scores of these ROIs were 
distributed as follows: 20.66 % (44) were low suspicion, 37.55% (80) were 
moderate suspicion, and 39.44% (84) were high suspicion. There was no MRI 
suspicion score reported for 5 of the ROIs. 
 
Overall Biopsy Results 
Including both 12-core mapping biopsy and targeted biopsy, the overall cancer 
detection rate was 42.66% (61 of 143 patients), and the clinically significant 
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cancer detection rate was 27.27% (39 of 143 patients). Of these men with cancer 
detected on mapping biopsy or targeted biopsy, 36.07% (22) had Gleason 3+3 
disease, 29.5% (18) had Gleason 3+4 disease, and 34.43% (21) had Gleason 
4+3 or greater disease. Between men with and without cancer found on mapping 
biopsy or targeted biopsy, there was no statistically significant difference in mean 
age (64.71 vs 63.68, p = 0.39), PSA (13.33 vs 10.29, p = 0.09), or number of 
previous biopsies (1.74 vs 1.89, p = 0.43). There was a difference in mean 
prostate volume as measured on MRI (50.62 vs 82.0, p < 0.01) and mean PSA 
density (0.29 vs 0.14, p < 0.01). Between men with and without clinically 
significant cancer found on mapping biopsy or targeted biopsy, there was no 
significant difference in mean number of previous biopsies (1.85 vs 1.82, p = 
0.89). There was a statistically significant difference in mean age (66.02 vs 63.4, 
p = 0.05), PSA (15.61 vs 10.08, p < 0.01), prostate volume on MRI (51.71 vs 
74.88, p < 0.01), and PSA density (0.34 vs 0.16, p < 0.01). Having an anteriorly 
located ROI was significantly correlated with detection of cancer (65.57% vs 
30.00%, p < 0.01) and detection of clinically significant cancer (44.26% vs 
10.00%, p < 0.01). 
 
Mapping Biopsy Results 
For standard 12-core mapping biopsy, the overall cancer detection rate was 
34.97% (50 of 143 patients), and the clinically significant cancer detection rate 
was 18.18% (26 of 143 patients). Of the men with cancer detected on mapping 
biopsy, 48.0% (24) had Gleason 3+3 disease, 22.0% (11) had Gleason 3+4 
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disease, and 30.0% (15) had Gleason 4+3 or greater disease. Between men with 
and without cancer found on mapping biopsy, there was no statistically significant 
difference in mean age (65.04 vs 63.6, p = 0.24) or number of previous biopsies 
(1.68 vs 1.90, p = 0.26). There was a significant difference in mean PSA (14.04 
vs 10.27, p = 0.04), prostate volume on MRI (50.62 vs 78.24, p < 0.01), and PSA 
density (0.31 vs 0.15, p < 0.01). Between men with and without clinically 
significant cancer found on mapping biopsy, there was no significant difference in 
mean number of previous biopsies (1.92 vs 1.80, p = 0.63). There was a 
statistically significant difference in mean age (67.77 vs 63.28, p < 0.01), PSA 
(18.43 vs 10.07, p < 0.01), prostate volume on MRI (50.82 vs 72.49, p = 0.03), 
and PSA density (0.41 vs 0.16, p < 0.01). For mapping biopsy, having an 
anteriorly located ROI was significantly correlated with detection of cancer 
(49.18% vs 28.33%, p = 0.02) but not correlated with detection of clinically 
significant cancer (26.23% vs 16.67%, p = 0.20). 
 
Targeted Biopsy Results 
For men who underwent targeted biopsies, the overall cancer detection rate of 
the targeted biopsies was 40.5% (49 of 121 patients), and the clinically significant 
cancer detection rate was 27.27% (33 of 121 patients). Of the men with cancer 
detected on targeted biopsy, 32.65% (16) had Gleason 3+3 disease, 28.57% (14) 
had Gleason 3+4 disease, and 38.78% (19) had Gleason 4+3 or greater disease. 
Between men with and without cancer found on targeted biopsy, there was no 
statistically significant difference in mean age (65.51 vs 63.51, p = 0.14) or 
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number of previous biopsies (1.88 vs 1.82, p = 0.79). There was a difference in 
mean PSA (14.00 vs 10.39, p = 0.05), prostate volume on MRI (51.84 vs 76.13, p 
< 0.01), and PSA density (0.31 vs 0.16, p < 0.01). Between men with and without 
clinically significant cancer found on targeted biopsy, there was again no 
significant difference in mean age (66.16 vs 63.61, p = 0.09) and number of 
previous biopsies (1.88 vs 1.83, p = 0.84). There was a statistically significant 
difference in mean PSA (16.87 vs 10.20, p < 0.01) prostate volume on MRI 
(52.03 vs 71.64, p = 0.02), and PSA density (0.35 vs 0.17, p < 0.01). For targeted 
biopsy, having an anteriorly located ROI was significantly correlated with 
detection of cancer (59.02% vs 21.67%, p < 0.01) and detection of clinically 
significant cancer (42.62% vs 11.67%, p < 0.01). 
 
Mapping Biopsy vs Targeted Biopsy 
In comparing the results of mapping biopsy and targeted biopsy for each patient, 
11 of the 93 patients (11.83%) who did not cancer found on mapping biopsy were 
found to have cancer on targeted biopsy. Of these 11, 6 were Gleason 3+3, 3 
were Gleason 3+4, and 2 were Gleason 4+3 or greater. Of the 24 patients who 
were found to have Gleason 3+3 disease on mapping biopsy, 5 (20.83%) were 
upgraded to Gleason 3+4 following targeted biopsy, and 3 (12.5%) were 
upgraded to Gleason 4+3 or greater. Only 1 of the 11 patients (9.09%) with 
Gleason 3+4 disease on mapping biopsy was found to have Gleason 4+3 
disease on targeted biopsy. In total, 21.50% (20 of 93) of patients were upgraded 
by inclusion of targeted biopsy. For the 72 patients found to have no cancer on 
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targeted biopsy, only 9 (12.5%) were found to have cancer on mapping biopsy. 
Seven of these were Gleason 3+3 disease, and the remaining 2 had Gleason 
4+3 or greater disease. Sixteen patients were found to have Gleason 3+3 
disease on targeted biopsy, and 4 of these 16 (25%) were found to have Gleason 
3+4 disease and none were found to have Gleason 4+3 or greater disease. Of 
the 14 patients with Gleason 3+4 disease on targeted biopsy, none were found to 
have Gleason 4+3 or greater disease on mapping biopsy. For the 22 patients 
with no target identified on MRI, 3 (13.64%) were found to have Gleason 3+3 
disease on mapping biopsy, and none were found to have any clinically 
significant cancer. Overall, 14 of 143 patients (9.79%) were upstaged in clinically 
significant risk category when targeted biopsy was added to mapping biopsy, 
while 6 (4.2%) were upstaged in clinically significant risk category when mapping 
biopsy was added to targeted biopsy. 
 
ROI-Level Results 
Cancer was found in 32.86% (70 of 213) of the ROIs. Clinically significant cancer 
was found in 22.54% (48 of 213) of the ROIs. Of the ROIs with cancer detected 
on targeted biopsy, 31.43% (22) had Gleason 3+3 disease, 28.57% (20) had 
Gleason 3+4 disease, and 40.00% (28) had Gleason 4+3 or greater disease. 
There was a strong correlation between MRI suspicion scores and presence of 
cancer, with cancer found in 47.62% of high suspicion ROIs, 26.25% of moderate 
suspicion ROIs, and 13.64% of low suspicion ROIs (p < 0.01). This relationship 
was also demonstrated for clinically significant cancer, with Gleason 3+4 or 
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greater disease found in 38.10% of high suspicion ROIs, 15.00% of moderate 
suspicion ROIs, and 6.82% of low suspicion ROIs. Between ROIs with and 
without cancer found on targeted biopsy, there was no significant correlation in 
location in terms of left vs right (p = 0.41) and base vs mid-gland vs apex (p = 
0.47). There was a statistically significant correlation regarding anterior vs 
posterior location (p < 0.01) and McNeal zone (p = 0.04). There was cancer 
found in 50.70% of anterior ROIs compared to 23.19% of posterior ROIs. 
Regarding McNeal zone, there was cancer found in 28.12% of ROIs in the 
peripheral zone, 40.00% of ROIs in the central or transitional zone, 71.43% of 
ROIs in the anterior stroma, and 0.00% of ROIs in the seminal vesicles. Between 
ROIs with and without clinically significant cancer found on targeted biopsy, there 
was again no correlation in terms of left vs right (p = 0.53) and base vs mid-gland 
vs apex (p = 0.21). There was a statistically significant correlation regarding 
anterior vs posterior location (p < 0.01) and McNeal zone (p < 0.01). There was 
clinically significant cancer found in 38.03% of anterior ROIs compared to 
15.22% of posterior ROIs. Regarding McNeal zone, there was cancer found in 
18.75% of ROIs in the peripheral zone, 27.50 % of ROIs in the central or 
transitional zone, 71.43% of ROIs in the anterior stroma, and 0.00% of ROIs in 
the seminal vesicles. 
 
Predicting Biopsy Results 
As discussed above, multiple factors were correlated with presence of clinically 
significant disease across biopsy methods in univariate analysis. Age, PSA, MRI 
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suspicion score, and PSA density were correlated with clinically significant 
disease in both mapping biopsy and targeted biopsy conditions. Anterior location 
of ROI was a particularly interesting factor, as it was significantly correlated with 
presence of cancer and higher grade cancer, particularly on targeted biopsy. In 
multivariate logistic regression with independent variables Age, PSA, PSA 
density, prostate volume on MRI, number of previous biopsies, MRI suspicion 
score, and presence of anteriorly located ROI, only high suspicion score (OR 
5.36, p = 0.02) and PSA density (OR 1.09 per 0.01 ng/mL2, p = 0.03) were 
significant independent predictors of clinically significant disease found on 
mapping or targeted biopsy. Presence of an anteriorly located ROI approached 
significance with odds ratio 2.56 (p = 0.07). For clinically significant cancer 
detected on mapping biopsy, multivariate logistic regression demonstrated that 
Age (OR 1.11, p = 0.03) and PSA density (OR 1.13 per 0.01 ng/mL2, p < 0.01) 
were significant independent predictors of disease. For clinically significant 
cancer detected on targeted biopsy, multivariate logistic regression revealed that 
the only significant independent predictor of disease was the presence of an 
anteriorly located ROI on mpMRI (OR 4.50, p < 0.01). High MRI suspicion score 
approached statistical significance with OR 3.88 (p = 0.10). Interestingly, PSA 
density was not a significant independent predictor of clinically significant disease 





Patients who present with a persistently elevated PSA and one or more prior 
negative prostate biopsies present a common management dilemma. Consensus 
guidelines for rebiopsy have not been determined, and the optimal method of 
rebiopsy continues to be investigated. An ideal approach would detect patients 
with clinically significant prostate cancer while avoiding morbidity related to 
excessive biopsies and the identification of low risk disease. In turn, this 
necessitates improved screening to better identify high risk patients within this 
population. It is common for men with continued suspicion for disease to undergo 
as many as 10 repeat biopsies 90. With advances in MRI technology and the 
development of MRI-US fusion biopsy, investigators have explored the utility of 
these advances for this population of patients. The results of our analysis 
contribute to this discussion. 
Multiple authors have compared the performance of MRI-targeted biopsy 
with both MRI in-bore and MRI-US fusion approaches to standard TRUS biopsy 
for patients with previous negative TRUS biopsies. Hambrock et al first described 
significantly higher cancer detection rates of 59% following MRI in-bore targeted 
biopsy, as compared to cancer detection rate of 15% in a matched cohort who 
received only TRUS biopsy. In the men who were found to have cancer, 48% 
were found to have Gleason ≥ 7 disease 94. Continuing this methodology, Hoeks 
et al reported a 41% cancer detection rate of in-bore MRI-guided targeted 
biopsies in a series of 265 men with elevated PSA and previous negative 
systematic TRUS biopsies 95. Meanwhile, other authors have described the 
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effectiveness of MRI-US fusion targeted biopsies in these patients. Utilization of 
the MRI-US fusion biopsy technology allowed for direct comparison of standard 
12-core biopsy cores with targeted biopsy cores in terms of cancer detection. 
Vourganti et al reported a targeted biopsy detection rate of 28.72% compared to 
23.08% for mapping biopsy in a population of 195 men. Of patients with cancer 
found on targeted biopsy, 71.42% were Gleason ≥ 7. Targeted biopsy was found 
to upgrade disease in 38.36% of the men with cancer found by either method, 
while missing only 5 cases of Gleason 7 disease 97. Sonn et al reported similar 
rates of cancer detection 98. Efforts to compare the two targeted biopsy methods 
have shown no difference between the two 102. Our findings are consistent with 
these rates, with overall cancer detection rate of 42.66%. Targeted biopsy had a 
cancer detection rate of 40.5% (67.35% Gleason ≥ 7) compared to 34.97% (52% 
Gleason ≥ 7) for mapping biopsy. Targeted biopsy upgraded 21.50% of patients 
with cancer found by either method, while missing only 6 cases of Gleason ≥ 7 
disease. As with other studies, we did not find any correlation between cancer 
detection rate and number of previous biopsies. Our data support the value of 
MRI-US fusion biopsy for patients with prior negative TRUS biopsies. 
In our analysis, no patients with a negative MRI were found to have 
Gleason ≥ 7 disease on standard biopsy. Increased MRI suspicion score was 
also correlated with higher grade disease and higher cancer detection rate on 
biopsy. Other studies have discussed this relationship between MRI suspicion 
score and predicted disease. Utilizing a 5-point Likert scale, Mendhiratta et al 
reported that MRI suspicion score < 4 carried a negative predictive value of 96% 
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for Gleason ≥ 7 disease. MRI suspicion score ≥ 4 was present in 22 of 26 men 
with Gleason ≥ 7, and MRI-US fusion targeted biopsy detected all 22 cases 101. 
In our analysis, 25 of the 38 men with Gleason ≥ 7 disease had a high MRI 
suspicion score. Though our negative predictive value of low or medium MRI 
suspicion score of 85% is not as high as that reported by Mendhiratta et al, we 
did have a 100% negative predictive value for negative MRI. Another recent 
cohort matched study by Abdi et al utilizing PI-RADS classification found that PI-
RADS score > 3 was associated with an odds ratio of 15.68 in predicting 
presence of Gleason ≥ 7 disease 99. On multivariate regression, we found an 
odds ratio of 5.36 for high MRI suspicion score in predicting Gleason ≥ 7 disease. 
While this is generally consistent with the findings from Abdi et al, we also found 
that high MRI suspicion score lost significance as an independent predictor when 
the analysis was divided into presence of significant disease found on each 
biopsy method. Our results support the notion that mpMRI has utility in predicting 
the presence of clinically significant disease and may even serve as a screening 
tool to risk-stratify men in this population.  
Beyond MRI suspicion score, our results highlighted the importance of 
anterior lesions found on mpMRI. Anterior lesions have been shown to represent 
the majority of tumors missed on standard TRUS biopsy 103. Vourganti et al noted 
the frequency of anterior tumors found in men with prior negative TRUS biopsies, 
diagnosing anterior disease in 33 of the 73 men (45.2%) with cancer 97. Other 
authors have investigated this relationship more closely. Volkin et al found a 
cancer detection rate of 42.4% for targeted biopsy of anterior lesions in patients 
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with prior negative TRUS biopsy versus a 29.3% detection rate with repeated 
TRUS biopsy 104. Our analysis found a cancer detection rate of 50.70% for 
targeted biopsy of anterior lesions, with 75% of those tumors containing Gleason 
≥ 7 disease. This is consistent with the values found by Volkin et al and 
comparable to those reported by Schouten et al, who utilized MRI in-bore 
targeted biopsy to achieve an overall cancer detection rate of 73%, with 70% of 
cancerous lesions located anteriorly and 65% of lesions with Gleason ≥ 7 105. We 
also evaluated the predictive value of having an anterior lesion for cancer 
detection. While having anterior lesions was not a significant predictor for 
clinically significant disease on mapping biopsy, it did predict the presence of 
clinically significant disease on targeted biopsy cores with odds ratio of 4.5. This 
builds on the idea that some anatomical locations of lesions seen on mpMRI may 
be more likely to harbor significant disease in men with previous negative 
biopsies. This region of the prostate is poorly sampled on standard TRUS biopsy, 
even when repeated multiple times. In this population, men should have some 
form of MRI-targeted biopsy to characterize lesions and achieve better sampling 
of those in more difficult anatomic positions. 
Further investigation of the relationship between clinically significant 
disease, MRI suspicion score, and anatomic location of lesions is warranted. 
Currently, MRI-targeted biopsy still fails to detect all cases of clinically significant 
cancer, confirming the need for continued mapping biopsy in all patients. With 
further advances in imaging technology, however, such as the use of contrast-
enhanced ultrasound by Jang et al, we may be able to better characterize and 
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target an even greater proportion of lesions within the gland 106. Optimal risk 
stratification of patients with prior negative biopsies will allow for the 
differentiation of those with indolent or insignificant disease from those with 
aggressive tumors while minimizing morbidity related to repeated prostate 
biopsies. 
The strengths of this study include the standardized protocol that all 
patients in the study period followed. MpMRIs were read and lesions were 
graded by one of a panel of radiologists, supporting the reproducibility of our MRI 
suspicion score grading system. MRI-US fusion biopsy was performed by a few 
experienced operators. Limitations of this study include its retrospective design, 
as our data was limited to the information available in patient charts. Many of our 
patients are referred from outside providers, and thus we are unable to assume a 
standardized technique of TRUS biopsy or pathological reading for previous 
biopsies. The potential for selection bias due to referral patterns to our institution 
limits the generalizability of our results. Despite these limitations, we believe that 
this study contributes to the ongoing discussion of the utility of prebiopsy mpMRI 






In men with one or more previous negative biopsies and continued suspicion for 
prostate cancer, mpMRI and MRI-US fusion targeted biopsy provide greater 
detection rate of clinically significant disease compared to standard 12-core 
TRUS biopsy. Men with negative MRI findings may be able to avoid or delay 
biopsy. Patients with high MRI suspicion score lesions and those with anterior 
lesions are at increased risk for significant disease and should be treated with the 
necessary diligence. Further investigation into the relationship between mpMRI, 
anatomic location of lesions, and effectiveness of MRI-targeted biopsy is required 
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Age	(mean) 64.11 64.71 63.68 0.386 66.02 63.40 0.046
PSA	(mean) 11.59 13.33 10.29 0.086 15.61 10.08 0.005
Previous	Biopsies	(mean) 1.83 1.74 1.89 0.428 1.85 1.82 0.893
MRI	Prostate	Volume	(mean) 68.52 50.62 82.00 <	0.001 51.71 74.88 0.006
PSA	Density	(mean) 0.20 0.14 0.29 <	0.001 0.16 0.34 <	0.001
MRIss
High 55 36	(65.45%) 19	(34.55%) 25	(45.45%) 30	(54.55%)
Moderate 24 13	(32.50%) 27	(67.50%) 8	(20.00%) 32	(80.00%)
Low 40 8	(33.33%) 16	(66.66%) 5	(20.83%) 19	(79.17%)
Negative	MRI 22 3	(13.64%) 19	(86.36%) 0	(0.00%) 22	(100.00%)
141 <	0.001 <	0.001
Has	Anterior	ROI 61 40	(65.57%) 21	(25.61%) <	0.001 27	(69.23%) 34	(32.69%) <	0.001
Gleason	≥	4+3 Gleason	3+4 Gleason	3+3 No	Cancer No	Target Totals
Gleason	≥	4+3 13 0 0 2 0 15
Gleason	3+4 1 6 4 0 0 11
Gleason	3+3 3 5 6 7 3 24
No	Cancer 2 3 6 63 19 93












High Moderate Low Total
11 5 3 19
19.30% 8.77% 5.26% 33.33%
9 6 3 18
15.79% 10.53% 5.26% 31.58%
16 2 2 20
28.07% 3.51% 3.51% 35.09%
36 13 8 57
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